Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$2.64 USD
+0.15 (5.82%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.67 +0.04 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for BioPath Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 14 | 10 | 11 | 9 |
Income After Depreciation & Amortization | -16 | -14 | -10 | -11 | -9 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -16 | -14 | -10 | -11 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -16 | -14 | -10 | -11 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -16 | -14 | -10 | -11 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -14 | -10 | -11 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -16 | -14 | -10 | -11 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.48 | 0.36 | 0.34 | 0.19 | 0.13 |
Diluted EPS Before Non-Recurring Items | -33.63 | -38.20 | -31.00 | -56.60 | -64.80 |
Diluted Net EPS (GAAP) | -33.63 | -38.20 | -31.00 | -56.60 | -64.80 |
Fiscal Year end for BioPath Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.04 | 3.27 | 4.24 | 5.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.04 | -3.27 | -4.24 | -5.29 |
Non-Operating Income | NA | -0.34 | 0.08 | 0.01 | 0.02 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.37 | -3.20 | -4.23 | -5.27 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.37 | -3.20 | -4.23 | -5.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.37 | -3.20 | -4.23 | -5.27 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 0.50 | 0.40 | 0.40 |
Diluted EPS Before Non-Recurring Items | NA | NA | -6.40 | -10.60 | -13.20 |
Diluted Net EPS (GAAP) | NA | -3.43 | -6.40 | -10.60 | -13.20 |